The International AIDS Society (IAS) conference, the biggest of its kind in the world, just closed in Australia. Its most significant conclusion is that the world must find a way to develop and deliver child-specific, side-effect-free (or limited) drugs to allow children with the disease to survive into adulthood (and perhaps to live to see a future in which the disease is eradicated).
Beyond hoary “children are the future” cliches, this proposal makes sense for a number of reasons. For one, call me a cynic, but the cliche is a great selling point. Finding a way to address in AIDS in children will inevitably capture hearts and imaginations in a way that simply addressing AIDS in Africa does not. But beyond the salesmanship, it seems logical to try to stanch the spread of a disease that has proven so fatal for children. Address the disease among its youngest victims while at the same time pushing for antiretroviral drugs geared toward adults and with side effects that can prove as dangerous to children as the disease they intend to attack. This is a strategy that seems both smart from a disease-combating perspective as well as from a marketing and political vantage point.
